TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Egetis Therapeutics AB (publ)
Closing information (x1000 DKK)
Closing information | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Turnover |
38,688
|
15,102
|
27,808 |
Financial expenses |
4,635
|
468
|
137 |
Earnings before taxes |
-219,503
|
-129,504
|
-76,016 |
EBITDA |
-215,742
|
-130,573
|
-75,059 |
Total assets |
510,607
|
374,946
|
413,933 |
Current assets |
232,332
|
98,498
|
111,180 |
Current liabilities |
69,787
|
33,011
|
28,482 |
Equity capital |
366,466
|
338,260
|
383,227 |
- share capital |
10,344
|
7,551
|
6,317 |
Employees (average) |
27
|
15
|
11 |
Financial ratios
Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Solvency |
71.8%
|
90.2%
|
92.6% |
Turnover per employee |
1,433
|
1,007
|
2,528 |
Profit as a percentage of turnover |
-567.4%
|
-857.5%
|
-273.4% |
Return on assets (ROA) |
-42.1%
|
-34.4%
|
-18.3% |
Current ratio |
332.9%
|
298.4%
|
390.4% |
Return on equity (ROE) |
-59.9%
|
-38.3%
|
-19.8% |
Change turnover |
23,509
|
-10,453
|
-1,759 |
Change turnover % |
155%
|
-41%
|
-6% |
Chg. No. of employees |
12
|
4
|
2 |
Chg. No. of employees % |
80%
|
36%
|
22% |
Total value of public sale
Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.